Evaluating CA-125 Indices in Ovarian Cancer
Author Information
Author(s): D.J. Cruickshank, J. Paul, C.R. Lewis, E.J. McAllister, S.B. Kaye
Primary Institution: University of Aberdeen; University of Glasgow; Gartnavel General Hospital
Hypothesis
Can CA-125 indices effectively predict treatment outcomes in patients with epithelial ovarian cancer?
Conclusion
The study found that CA-125 indices have limited clinical utility for predicting treatment failures in ovarian cancer.
Supporting Evidence
- 39 patients (48%) progressed clinically or died within 1 year of treatment.
- The maximum sensitivity obtained for CA-125 indices was 46% with a specificity just exceeding 90%.
- Statistically significant associations were observed between CA-125 parameters and treatment outcomes.
Takeaway
Doctors looked at a blood test called CA-125 to see if it could help tell which ovarian cancer patients would do well with treatment and which wouldn't, but it didn't work as well as hoped.
Methodology
CA-125 levels were measured before each of the first three chemotherapy cycles in patients with ovarian cancer, and logistic regression was used to assess predictive values.
Potential Biases
There may be bias in patient selection and the interpretation of CA-125 levels due to variability in clinical practice.
Limitations
The study's findings may not be generalizable due to the specific patient population and the fact that not all patients had CA-125 measurements taken.
Participant Demographics
Median age was 59 years, with a range from 21 to 78 years; 54% had residual disease greater than 2 cm.
Statistical Information
P-Value
0.013
Confidence Interval
[15%-49%]
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website